Table 6.
Summary of outcomes for rimonabant
| Outcome | No of studies (sample size) | Weighted mean difference or risk difference (active minus placebo) (95% CI) |
|---|---|---|
| Change in weight (kg) | 4 (4099) | −4.67 (−5.26 to −4.07) |
| 5% responders (absolute % difference) | 4 (4099) | 0.33* (0.29. 0.37) |
| 10% responders (absolute % difference) | 4 (4099) | 0.19* (0.15 to 0.23) |
| Change in: | ||
| Waist circumference (cm) | 4 (4098) | −3.89 (−4.47 to −3.30) |
| Systolic blood pressure (mm Hg) | 3 (2273) | −1.78 (−2.81 to −0.76) |
| Diastolic blood pressure (mm Hg) | 3 (2273) | −1.23 (−1.93 to −0.54) |
| Total cholesterol (mmol/l) | 3 (2223) | −0.04 (−0.11 to 0.03) |
| Low density lipoprotein cholesterol (mmol/l) | 3 (2223) | −0.05 (−0.12 to 0.01) |
| High density lipoprotein cholesterol (mmol/l) | 4 (4050) | 0.10 (0.08 to 0.11) |
| Triglycerides (mmol/l) | 4 (4049) | −0.24 (−0.30 to −0.17) |
| Weight in those with diabetes (kg) | 1 (1047) | −3.90 (−4.57 to −3.23) |
| Haemoglobin A1C in those with diabetes (%) | 1 (1047) | −0.70 (−0.84 to −0.56) |
| Fasting glucose in those with diabetes (mmol/l) | 1 (1047) | −0.97 (−1.30 to −0.64) |
| Discontinuation because of adverse event (absolute % difference) | 4 (4105) | 0.06* (0.05 to 0.08) |
| Serious adverse event (absolute % difference) | 4 (4105) | 0.02* (0.00 to 0.03) |
| Psychiatric disorders (absolute % difference) | 4 (4105) | 0.03* (0.02 to 0.05) |
*Risk difference. All other calculations represent weighted mean difference.